Breast Cancer Service

ATTENTION: This page is being updated. Thank you for your patience.

The Breast Cancer Service at the Segal Cancer Centre is internationally renowned and includes the following

  1. Prevention program.
  2. One of the Quebec-designated screening and early diagnostic centres (CRID).
  3. Fully integrated surgical-medical-radiation oncology services.
  4. Expertise in breast reconstruction.
  5. Access to the very latest in treatment options.
  6. Lymphedema program.
  7. Genetics program
  8. Tumour registry

Medical Director: Mark Basik, MD

The study and treatment of breast cancer has long been a preoccupation of the Jewish General Hospital. Beginning in the early 1970s, Dr. Richard Margolese brought the hospital and its patients to a central position in the rapidly evolving area of treatment through our participation in the National Surgical Adjuvant Breast and Bowel Project (NSABP). Our patients were thus a part of dramatic changes in treatment (e.g. lumpectomy instead of mastectomy; chemotherapy and hormonal therapy following surgery to prevent tumour spread).

How to reach us

Segal Cancer Centre

Pavillion E, 7th floor, (E-728)
Jewish General Hospital
Tel: (514) 340-8248  

CRID Radiologie

Pavilion E, 10th floor 
Mon - Fri: 8am - 4pm 
​​Tel: (514) 340-7997 
Fax: (514) 340-7942 

Rapid Investigation Clinic (Nurse Navigator and Physician) 

If you are undergoing a breast biopsy at our hospital in the CRID, our Rapid Investigation Clinic is here to support you through the process. This clinic provides specialized care with a Nurse Navigator and a physician to guide you at every step and discuss your results.  

For Biopsy Patients Only: 

Nurse Navigator:  

  • Lindsay Schwartz 

  • Mandy Collins 

 Pavilion E, Level 7, Room 740 (E-740) 
Monday to Friday, 8:00 AM – 4:00 PM 
Tel: (514) 340-8222, ext. 29626 

Oncology Pivot Nurse 

Tel: (514) 340-8222 ext 22361 / 23562 

  • Erika Martinez 
  • Brandy Vanderbyl  

Breast Surgery Clinic (Surgeons) 

Pavilion E, 7th floor 
Mon-Fri: 8 am - 4 pm 
Tel: 514-340-8222 ext. 24210 
Fax: 514-340-8302 

Our Care

Breast Referral and Investigation Centre

In 1998, the Quebec Breast Cancer Screening Program (PQDCS) started emphasizing the need for screening and encouraging women to do a mammogram every two years in one of the designated radiology centres. As a result, all women in Quebec aged 50-74 are now automatically sent a letter to sensitize them to the importance of screening. When an abnormal or suspicious result is found, the patient is referred to a specialized centre, the Breast Referral and Investigation Centre (Centre de référence et d’investigation désigné or CRID). The CRID provides expertise in investigation (additional workup involving special views, ultrasounds, MRI) and diagnosis (stereotactic biopsy,  ultrasound biopsy or MRI guided biopsy). Women are cared for by a competent team who provides individualized and compassionate care. Many women will leave the Centre with good news but some will need surgery. They will be informed, supported and guided through a trajectory of care oriented towards their specific needs. The Nurse Navigator from the Rapid Investigation Clinic will link with the Oncology Pivot Nurse and one of the specialized breast surgeons in the Breast Clinic. 

What to expect when you require a biopsy: Read more about the biopsy procedure in our Patient Guides for Breast Biopsies available on the page for the Rapid Investigation Clinic.  

1. Mammography

A mammogram uses low dose x-ray images of the breast to identify  masses, abnormal nodules, or calcium deposits (microcalcifications). Screening mammograms are used for early detection of breast cancer in women without any signs or symptoms of cancer. Diagnostic mammograms are used to further evaluate breast tissue in women who have signs of cancer or an abnormality on screening mammogram.  Diagnostic mammograms often involve magnifying breast tissue or taking additional pictures/views of the breast to allow the radiologist to better pinpoint and examine the area of possible concern. 

2. Breast Ultrasound

An ultrasound uses high-frequency sound waves to take pictures of the inside of the breast, and is commonly used before or after a mammogram to better evaluate breast tissue. Ultrasounds can help determine if a breast lump or abnormality is a benign nodule, cyst, or a suspicious mass. An ultrasound can also help to identify the location of a breast lump for biopsy.

3. Image Guided Biopsies

A biopsy is a procedure where a small sample of tissue is removed from the breast and examined under the microscope. Image-guided biopsies include biopsies performed with the help of ultrasound (ultrasound-guided biopsy), mammogram (stereotactic biopsy), or MRI (MRI-guided biopsy) to locate the precise area of the abnormality. 

If a biopsy is required, you will be contacted by our Nurse Navigator in our Rapid Investigation Clinic. They will speak to you prior to your biopsy date to review your medications, any allergies, and help you prepare for the biopsy procedure. Please bring your medication list to your appointment. The biopsy results will be sent to your referring physician. The physicians in the Rapid Investigation Clinic are available to discuss your results and will refer you to a healthcare professional if needed.  

What to expect when you require a biopsy: Read more about the biopsy procedure in our Patient Guides for Breast Biopsies available on the page for the Rapid Investigation Clinic.  

4. Bilateral Breast MRI

Breast MRI involves lying face down in a scanning machine that uses magnetic fields to look inside the breast. MRI and mammograms are used together to screen women at very high risk of developing breast cancer. Diagnostic MRIs can also be used to help evaluate a breast cancer when other imaging tests do not show clear results, or when patients need additional treatment before surgery like chemotherapy. Please note our MRI department is located in general radiology, Pavilion D, 2nd Floor, Room D-205.

Treatment

We approach the management of breast cancer with an interdisciplinary team. Patients are seen in a mulit-disciplinary clinic by medical and surgical oncologists as well as the nurse (infirmière pivot), who will accompany them during diagnosis and treatment. Psychosocial support professionals, psychologists, volunteer services and symptom management expertise are on hand as well. All cases are routinely discussed at the weekly Tumour Board Conference where the team determines the optimal treatment. Our medical oncologists are leaders in the field, and working with expert pharmacists and nurses, they provide the very latest in treatment options. The Jewish General Hospital provides access to many novel treatment options, through participation in clinical trials which are conducted either through the Clinical Research Unit in the Cancer Centre or via the McGill Clinical Research Program, Women’s Cancer Committee (chaired by Dr. Panasci) Thus, there are many opportunities for patients to participate in the most innovative clinical trials testing the very newest treatments.

Oncology Pivot Nurse

Our pivot nurses will help educate you regarding your diagnosis, surgery, and treatment through one-on-one meetings or their monthly group information sessions. If you are diagnosed with breast cancer and would like to discuss what resources are available to you, we encourage you to contact them.  Following surgery, they are also an excellent resource if you have any questions or concerns, or require additional support. 

Support

The Breast Cancer Program is committed to providing for the needs of the patients and their families. Health care professionals are available to provide help in pain and symptom control. In addition, the psychosocial support team of psychiatrists, psychologists and social workers are on hand as are trained volunteers.

Hope & Cope

Hope & Cope offers a wide variety of support and educational services to breast cancer patients and their families. Guided by professional staff, our services are offered free of charge by cancer-experienced volunteers. Services include different types of support groups, available online or in person for those newly diagnosed or with advanced cancer. They have Breast Cancer Support Groups that offer a welcoming space for individuals newly diagnosed with breast cancer to share experiences, gain insights, and find emotional support among peers navigating similar journeys. They also offer various workshops such as the "Look Good, Feel Better" workshop, which teaches women techniques for makeup application and dealing with hair loss, and the "Think Smart, Live Well" workshops which provide practical strategies for coping with cancer and every day stress, public lectures and an easily accessible information resource centre. As well, the JGH Hope & Cope Wellness Centre, located close to the hospital, offers a variety of complementary therapies such as yoga, Qi Gong, Tai Chi, art therapy, relaxation, an exercise facility and a nutrition program. All programs are free of charge and open to all patients regardless of hospital affiliation.

Learn more about  Hope & Cope 

Lymphedema Clinic

The Lymphedema clinic of the Jewish General Hospital is the first hospital clinic in Montreal to offer the evaluation as well as the treatment of lymphedema secondarily to cancer treatments. Lymphedema is an abnormal accumulation of protein fluid in tissues and it comes as the result of surgery and/or radiotherapy. The clinical signs of lymphedema are swelling, discomfort, loss of function of the affected limb leading to an increase risk of infection and a significant psychological impact. Combined Decongestive Therapy is the recommended therapy and it consists of two phases: the manual intensive drainage phase (exercises, bandages, skin care) and the maintenance phase (focused on prevention of relapse of lymphedema). We offer advice on prevention and decreasing the risk of lymphedema. Our clinic is open to patients followed by an oncologist or by a physician of the JGH.

Learn more about the Lymphedema clinic

Prevention

In our Cancer Prevention Centre, we provide comprehensive care to patients and family members facing hereditary breast cancer. Our internationally recognized research in this area allows us to provide care to these families with the very latest knowledge base. Through public information sessions and availability of state-of-the-art clinical trials, we are at the forefront of breast cancer prevention.

Clinical Trials

Please see below a list of our current clinical trials for breast cancer. 

Last updated: February 8, 2024

Early Stage Breast Cancer

Including neoadjuvant, adjuvant and local therapy clinical trials.

HER2+
(Neoadjuvant)

 DESTINY Breast11: A Phase 3 open-label trial of neoadjuvant Trastuzumab Deruxtecan (T-DXd) monotherapy or T-DXd followed by THP compared to ddAC-THP in participants with high-risk
HER2-positive early-stage breast cancer 

HER2+
(Neoadjuvant)

 ProHer: A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer (closed to accrual)

ER+HER2-
(Neoadjuvant)

 KEYNOTE 756: Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (closed to accrual)      

ER+HER2-
(Adjuvant)

 NRG-BR009 The OFSET Study: A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression and Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score of ≤ 25 (coming soon)

ER+HER2-
(Adjuvant)

 EMBER-4: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

ER+HER2-
(Adjuvant)

 LALEAST: Limited Adjuvant Endocrine Therapy for Low Risk Breast Cancer. Phase II trial of 2 years of standard adjuvant endocrine therapy after low risk hormone receptor positive, HER2 negative, node negative breast cancer in women older than 50 at diagnosis (closed to accrual)

HER2+
(Adjuvant)

 DESTINY-Breast05 / NSABP B-60: A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (closed to accrual)

TNBC
(Post neoadjuvant)

 TROPION-Breast03: A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy

TNBC (Neoadjuvant)

 TROPION-Breast04: A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer

TNBC  (Adjuvant)

 TRICIA: TRIple Negative Breast Cancer Markers In Liquid Biopsies Using Artificial Intelligence

SURGERY

 TADEN: Sentinel Node Biopsy and Targeted Axillary Dissection in Node Positive Breast Cancer Patients with Clinically Negative Axilla

SURGERY

 TAXIS: Tailored Axillary Surgery With or Without Axillary Lymph Node Dissection Followed by Radiotherapy in Patients With Clinically Node-positive Breast Cancer

RADIATION

 Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast Cancer

RADIATION

 Tailor RT (MA 39): A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive and T3N0 Breast Cancer

BRCA+
(Unaffected or Adjuvant)

 CHARM: Cell-free DNA in Hereditary And High-Risk Malignancies (closed to accrual)

Metastatic Breast Cancer

Including recurrent or de novo metastatic breast cancer trials.

TNBC

 TROPION-Breast03:  A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy

HER2+

KATE 3: A randomized, multicenter, double blind, placebo-controlled phase 3 study of the efficacy and safety of trastuzumab emtansine in combination with atezolizumab or placebo in
patients with Her2-positive and pd-L1-positive locally advanced or metastatic breast cancer who have
received prior trastuzumab- (+/- pertuzumab) and taxane-based therapy

ER+HER2-
 

 SERENA-4 - D8532C00001: A randomized, multicentre, double-blind, phase 3 study of AZD9833 (an oral serd) plus palbociclib versus anastrozole plus palbociclib for the treatment of patients with estrogen receptor-positive, her2- negative advanced breast cancer who have not received any systemic treatment for advanced disease.      

ER+HER2-
 

 persevERA / BO41843: Phase III-Study, Double Blind, Evaluating the Efficacy and Safety of GDC-9545 Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer 

ER+HER2low
 

 DESTINY BREAST 06: A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) Versus Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Breast Cancer Patients Whose Disease Has Progressed on Endocrine Therapy in the Metastatic Setting

ER+HER2-
 

 KEYNOTE B-49: Randomised, Double-blind, Placebo-controlled,Phase 3 Study of Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for the treatment of Chemotherapy-Candidate Hormone Receptor-Positive, Human Epidermal Growth factor receptor 2-Negative (HR+,HER2-) Metastatic Breast cancer.

ER+HER2-
 

 WO41554 (INAVO120): A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Patients With PIK3CA-Mutant, Hormone Receptor-Positive, Her2-Negative, Locally Advanced or Metastatic Breast Cancer

HER2+

 HER2 CLIMB-02: A Phase III A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer (closed to accrual)

Page last updated on 

We always seek feedback to make our site better.